Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.47 |
| ▸ | ATXN2 | Q99700 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16979283 | 0.87 | CYP3A4 (0.51) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL30746332 | 0.86 | MEN1 (0.51) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL2674601 | 0.86 | MEN1 (0.58) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL29413615 | 0.84 | KMT2A (0.55) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL25878472 | 0.82 | MEN1 (0.54) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL25486481 | 0.82 | MEN1 (0.61) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL12835941 | 0.82 | MEN1 (0.54) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL10153538 | 0.82 | MEN1 (0.54) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL3551987 | 0.82 | MEN1 (0.54) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL27194542 | 0.81 | MEN1 (0.47) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584258-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250170248-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250161465-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12156916-B2 | Rapid accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-20240156968-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240156967-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-05-16 | — | — | US | disclosed |
| EP-4363425-A1 | SMARCA DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11957759-B1 | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| WO-2024054591-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| WO-2023278402-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| US-9550793-B2 | Spirocyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-01-24 | — | — | US | disclosed |
| US-9550793-B2 | Spirocyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-01-24 | — | — | US | disclosed |
| US-9550793-B2 | Spirocyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-01-24 | — | — | US | disclosed |
| EP-2903985-A1 | SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | Advinus Therapeutics Limited (IN) | 2015-08-12 | — | — | EP | disclosed |
| US-20150218187-A1 | SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2015-08-06 | — | — | US | disclosed |
| US-20150218187-A1 | SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2015-08-06 | — | — | US | disclosed |
| US-20150218187-A1 | SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2015-08-06 | — | — | US | disclosed |
| WO-2014054053-A1 | SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2014-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218187-A1 | SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | DGAT1, DGAT2, CPT1A | MEN1 2640/4885KMT2A 2800/4885NPSR1 2678/4885 |
| US-12156916-B2 | Rapid accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use | BRAF, ARAF, RAF1 | MEN1 4032/4885KMT2A 699/4885NPSR1 4132/4885 |
| US-20250170248-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | MEN1 2085/4885KMT2A 73/4885NPSR1 4481/4885 |
| US-20240156968-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARAF, BRAF, HRAS | MEN1 3861/4885KMT2A 1934/4885NPSR1 4209/4885 |
| US-20240156967-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | BRAF, ARAF, RAF1 | MEN1 4014/4885KMT2A 773/4885NPSR1 4155/4885 |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | MEN1 2085/4885KMT2A 73/4885NPSR1 4481/4885 |
| US-20250161465-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARAF, BRAF, HRAS | MEN1 3861/4885KMT2A 1934/4885NPSR1 4209/4885 |
| US-11957759-B1 | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use | BRAF, ARAF, RAF1 | MEN1 3958/4885KMT2A 738/4885NPSR1 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.